Colorectal cancer in younger adults is not just the same disease arriving early — it is biologically different, according to new research from Dana-Farber Cancer Institute and collaborators, published in Nature Medicine.
The team analysed 189 colorectal tumours from patients aged 29 to over 90, measuring gene activity in more than 850,000 individual cells using single-nucleus RNA sequencing. It is the largest study of its kind comparing early-onset disease (diagnosed at or below 50) with average-onset disease.
They found that tumours from younger patients contain proportionally more stromal cells and fewer epithelial cells than tumours from older patients — differences in the mix of cell types that may affect how the cancer behaves and how it responds to treatment.
The findings matter because diagnoses are climbing: in the United States, colorectal cancer diagnosis rates among people under 50 rose 2.9% per year from 2013 through 2022, according to the American Cancer Society, and the disease is now the leading cause of cancer death in that age group.
The researchers are careful about the limits: the study does not prove these cellular differences cause the more aggressive disease doctors often see in younger patients, and their method captured relatively few immune cells, leaving the immune picture incomplete.
Even so, the work gives researchers a map of where to look next — and strengthens the case for taking symptoms in younger adults seriously rather than assuming they are too young for bowel cancer.
Sources: Dana-Farber Cancer Institute (29 Oct 2026); Porter et al., Nature Medicine (2026), DOI: 10.1038/s41591-026-04721-y; reporting via News-Medical.